160 related articles for article (PubMed ID: 18798733)
1. Three researchers developing therapies based on RNA interference talk about their experiences leaving academia for biotech companies.
Bonetta L
Biotechniques; 2007 Apr; 42(4 Suppl):S10-11, S16. PubMed ID: 18798733
[No Abstract] [Full Text] [Related]
2. Making big drugs. Interview by Geoff Colvin.
Sharer K
Fortune; 2009 Jul; 160(2):31-6. PubMed ID: 19685798
[No Abstract] [Full Text] [Related]
3. Alejandro Zaffaroni (1923-2014).
Shaw JE
Nature; 2014 Apr; 508(7495):187. PubMed ID: 24717508
[No Abstract] [Full Text] [Related]
4. Ten years on--the European perspective. Biotech company founders talk about what made their companies tick.
Collingham DP
Biotechnology (N Y); 1993 Mar; 11(3):S44-6. PubMed ID: 7763435
[No Abstract] [Full Text] [Related]
5. The biopharmaceutical industry in China: history and future perspectives.
Gao K; Wang J
Front Med; 2012 Jun; 6(2):101-11. PubMed ID: 22544299
[TBL] [Abstract][Full Text] [Related]
6. Perspectives: biotechnology in Czech Republic, the past and the future.
Damborský J; Prokop Z; Kostka M
Biotechnol J; 2006 May; 1(5):487-90. PubMed ID: 16892283
[No Abstract] [Full Text] [Related]
7. Profile: William Haseltine.
Herrera S
Nat Biotechnol; 2005 Aug; 23(8):913. PubMed ID: 16082351
[No Abstract] [Full Text] [Related]
8. Profile: Jean-Paul Clozel.
Schmidt C
Nat Biotechnol; 2007 Feb; 25(2):155. PubMed ID: 17287737
[No Abstract] [Full Text] [Related]
9. Abe Abuchowski.
Katsnelson A
Nat Biotechnol; 2006 Sep; 24(9):1050. PubMed ID: 16964200
[No Abstract] [Full Text] [Related]
10. "Extraordinary Measures": Arrowsmith for the NASDAQ era.
Weissmann G
FASEB J; 2010 Apr; 24(4):963-7. PubMed ID: 20356907
[No Abstract] [Full Text] [Related]
11. An interview with Martin Rosenberg, Ph.D. Interviewed by Vicki Glaser.
Rosenberg M
Assay Drug Dev Technol; 2009 Dec; 7(6):537-43. PubMed ID: 20035618
[No Abstract] [Full Text] [Related]
12. Profile: Una Ryan.
Schmidt C
Nat Biotechnol; 2006 Aug; 24(8):881. PubMed ID: 16900115
[No Abstract] [Full Text] [Related]
13. Masters of their universe.
Osborne R; DeFrancesco L
Nat Biotechnol; 2009 Jun; 27(6):528-30. PubMed ID: 19513053
[TBL] [Abstract][Full Text] [Related]
14. A brief history of novel drug discovery technologies.
Gershell LJ; Atkins JH
Nat Rev Drug Discov; 2003 Apr; 2(4):321-7. PubMed ID: 12669031
[TBL] [Abstract][Full Text] [Related]
15. Profile: Corey Goodman.
Kling J
Nat Biotechnol; 2009 Apr; 27(4):308. PubMed ID: 19352358
[No Abstract] [Full Text] [Related]
16. Who's who in biotech.
Jayaraman KS; Louët S; Powell K; Ransom J; Sheridan C; Vastag B; Waltz E
Nat Biotechnol; 2006 Mar; 24(3):291-300. PubMed ID: 16525392
[No Abstract] [Full Text] [Related]
17. Profile: Jean Deleage.
Ratner M
Nat Biotechnol; 2005 Oct; 23(10):1197. PubMed ID: 16211047
[No Abstract] [Full Text] [Related]
18. Profile: Thomas Lönngren.
Louët S
Nat Biotechnol; 2004 Nov; 22(11):1341. PubMed ID: 15529143
[No Abstract] [Full Text] [Related]
19. Remembering Marvin Weinstein (1916-2011).
Demain AL; Weinstein RN
J Antibiot (Tokyo); 2012 Jul; 65(7):381-2. PubMed ID: 22836814
[No Abstract] [Full Text] [Related]
20. Mexico, the father of the pill and the race for cortisone.
Renneberg R
Biotechnol J; 2008 Apr; 3(4):449-51. PubMed ID: 18412173
[No Abstract] [Full Text] [Related]
[Next] [New Search]
